60
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Properdin and Factor H: Opposing Players on the Alternative Complement Pathway “See-Saw”

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Properdin and factor H are two key regulatory proteins having opposite functions in the alternative complement pathway. Properdin up-regulates the alternative pathway by stabilizing the C3bBb complex, whereas factor H downregulates the pathway by promoting proteolytic degradation of C3b. While factor H is mainly produced in the liver, there are several extrahepatic sources. In addition to the liver, factor H is also synthesized in fetal tubuli, keratinocytes, skin fibroblasts, ocular tissue, adipose tissue, brain, lungs, heart, spleen, pancreas, kidney, muscle, and placenta. Neutrophils are the major source of properdin, and it is also produced by monocytes, T cells and bone marrow progenitor cell line. Properdin is released by neutrophils from intracellular stores following stimulation by N-formyl-methionine-leucine-phenylalanine (fMLP) and tumor necrosis factor alpha (TNF-α). The HEP G2 cells derived from human liver has been found to produce functional properdin. Endothelial cells also produce properdin when induced by shear stress, thus is a physiological source for plasma properdin. The diverse range of extrahepatic sites for synthesis of these two complement regulators suggests the importance and need for local availability of the proteins. Here, we discuss the significance of the local synthesis of properdin and factor H. This assumes greater importance in view of recently identified unexpected and novel roles of properdin and factor H that are potentially independent of their involvement in complement regulation.

          Related collections

          Most cited references117

          • Record: found
          • Abstract: found
          • Article: not found

          Inflammation and neurodegeneration in Parkinson's disease.

          The immunohistochemical demonstration of reactive microglia and activated complement components suggests that chronic inflammation occurs in affected brain regions in Parkinson's disease (PD). Evidence from humans and monkeys exposed to MPTP indicates this inflammation may persist many years after the initial stimulus has disappeared. Chronic inflammation can damage host cells. Reports in the literature indicate that antiinflammatory agents inhibit dopaminergic cell death in animal models of PD, and there is one epidemiological report that their use significantly diminishes the risk of PD in humans. There is a marked elevation in the mRNA levels for complement proteins and markers of activated microglia in affected regions in PD. The upregulation appears greater than that found in inflamed arthritic joints. These data support the hypothesis that chronic inflammation may play an important role, if secondary, in the pathogenesis of PD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Evolution of the lectin-complement pathway and its role in innate immunity.

            Discrimination between self and non-self by lectins (carbohydrate-binding proteins) is a strategy of innate immunity that is found in both vertebrates and invertebrates. In vertebrates, immune recognition mediated by ficolins (lectins that consist of a fibrinogen-like and a collagen-like domain), as well as by mannose-binding lectins, triggers the activation of the complement system, which results in the activation of novel serine proteases. The presence of a similar lectin-based complement system in ascidians, our closest invertebrate relatives, indicates that the complement system probably had a pivotal role in innate immunity before the evolution of an adaptive immune system in jawed vertebrates.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.

              Neisseria meningitidis binds factor H (fH), a key regulator of the alternative complement pathway. A approximately 29 kD fH-binding protein expressed in the meningococcal outer membrane was identified by mass spectrometry as GNA1870, a lipoprotein currently under evaluation as a broad-spectrum meningococcal vaccine candidate. GNA1870 was confirmed as the fH ligand on intact bacteria by 1) abrogation of fH binding upon deleting GNA1870, and 2) blocking fH binding by anti-GNA1870 mAbs. fH bound to whole bacteria and purified rGNA1870 representing each of the three variant GNA1870 families. We showed that the amount of fH binding correlated with the level of bacterial GNA1870 expression. High levels of variant 1 GNA1870 expression (either by allelic replacement of gna1870 or by plasmid-driven high-level expression) in strains that otherwise were low-level GNA1870 expressers (and bound low amounts of fH by flow cytometry) restored high levels of fH binding. Diminished fH binding to the GNA1870 deletion mutants was accompanied by enhanced C3 binding and increased killing of the mutants. Conversely, high levels of GNA1870 expression and fH binding enhanced serum resistance. Our findings support the hypothesis that inhibiting the binding of a complement down-regulator protein to the neisserial surface by specific Ab may enhance intrinsic bactericidal activity of the Ab, resulting in two distinct mechanisms of Ab-mediated vaccine efficacy. These data provide further support for inclusion of this molecule in a meningococcal vaccine. To reflect the critical function of this molecule, we suggest calling it fH-binding protein.
                Bookmark

                Author and article information

                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                18 March 2013
                23 April 2013
                2013
                : 4
                : 93
                Affiliations
                [1] 1Centre for Infection, Immunity and Disease Mechanisms, Biosciences, School of Health Sciences and Social Care, Brunel University London, UK
                [2] 2Department of Pharmacology, University of Oxford Oxford, UK
                [3] 3Centre for Biotechnology and Bioinformatics, School of Life Sciences, Jawaharlal Nehru Institute for Advanced Studies Secunderabad, Andhra Pradesh, India
                [4] 4Department of Infection, Immunity and Inflammation, University of Leicester Leicester, UK
                [5] 5Faculty of Science, Engineering and Computing Kingston upon Thames, Surrey, UK
                Author notes

                Edited by: Berhane Ghebrehiwet, Stony Brook University, USA

                Reviewed by: Viviana P. Ferreira, University of Toledo, USA; Chenhui Zou, Brigham and Women’s Hospital, USA

                *Correspondence: Uday Kishore, Centre for Infection, Immunity and Disease Mechanisms, Biosciences, School of Health Sciences and Social Care, Brunel University, London UB8 3PH, UK. e-mail: uday.kishore@ 123456brunel.ac.uk ; ukishore@ 123456hotmail.com

                Lubna Kouser and Munirah Abdul-Aziz have contributed equally to this work.

                This article was submitted to Frontiers in Molecular Innate Immunity, a specialty of Frontiers in Immunology.

                Article
                10.3389/fimmu.2013.00093
                3632793
                23630525
                8920bb2c-52e8-4cf5-a3d1-82484013733d
                Copyright © 2013 Kouser, Abdul-Aziz, Nayak, Stover, Sim and Kishore.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

                History
                : 21 February 2013
                : 05 April 2013
                Page count
                Figures: 2, Tables: 4, Equations: 0, References: 127, Pages: 12, Words: 11126
                Categories
                Immunology
                Review Article

                Immunology
                properdin,factor h,biosynthesis,complement,extrahepatic
                Immunology
                properdin, factor h, biosynthesis, complement, extrahepatic

                Comments

                Comment on this article